Article
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Molecular oncology - 1 Jan 2021
Sakai Kazuko, Takahama Takayuki, Shimokawa Mototsugu, Azuma Koichi, Takeda Masayuki, Kato Terufumi, Daga Haruko, Okamoto Isamu, Akamatsu Hiroaki, Teraoka Shunsuke, Ono Akira, Ohira Tatsuo, Yokoyama Toshihide, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Nishio Kazuto
Abstract excerpt
The WJOG8815L phase II clinical study involves patients with non-small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third-generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.